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Open access under CC BY-NReply to: ‘‘Is industrial fructose just a marker
of an unhealthy dietary pattern?’’To the Editor:
We recently reported a link between fructose intake and the
severity of liver ﬁbrosis in a cohort of Italian patients with
genotype 1 (G1) chronic hepatitis C (CHC) [1]. In particular, the
association holds true for ‘‘industrial’’ only, not for ‘‘fruit’’
fructose intake.
We thank Chiavaroli and colleagues for their comments that
give us the opportunity to further strengthen data from our
analyses.Journal of Hepatology 20
C-ND license.Firstly, they question the approach we used for the multivar-
iate model assessing variables independently associated with
severe liver ﬁbrosis. Speciﬁcally, they raised concerns about the
lack of adjustment for energy intake, a variable associated in
our analysis with industrial fructose intake, not with liver ﬁbro-
sis. From a methodological point of view the choice of indepen-
dent variables included in the ﬁnal multivariate analysis is not
a simple task, particularly in relatively small databases. To
enhance the accuracy of the model, the number of independent14 vol. 61 j 169–182 173
Table 1. Multivariate analysis of risk factors associated with severe ﬁbrosis (F3–F4) in 147 patients with chronic hepatitis C by logistic regression analysis.
Variable 
n = 114
Non-severe fibrosis Severe fibrosis
n = 33
Univariate analysis Multivariate analysis
p value OR (95% CI) p value
Age (yr) 54.7 ± 11.0 59.1 ± 10.4 0.04 1.046 (0.993-1.100) 0.08
Waist circumference (cm) 94.6 ± 11.4 98.7 ± 10.4 0.06 1.019 (0.974-1.067) 0.41
Histology at biopsy 
Severe grading
Moderate-severe steatosis
Features of NASH
28/86
28/86
6/108
19/14
17/16
7/26
<0.0001
0.003
0.004
3.616 (1.373-9.526)
2.462 (0.861-7.045)
4.185 (1.010-17.676)
0.009
0.09
0.04
Kilocalories* 1910.8 ± 695.9 1987.3 ± 561.8 0.56 1.001 (0.998-1.002) 0.44
Proteins amount* (%) 16.6 ± 2.9 16.9 ± 3.5 0.60 1.156 (0.988-1.354) 0.07
Cholesterol* (mg) 223.9 ± 115.1 215.0 ± 98.9 0.69 0.999 (0.994-1.006) 0.86
Saturated fats* (g) 19.9 ± 9.9 18.9 ± 8.4 0.60 0.938 (0.838-1.050) 0.26
Monounsaturated fats* (g) 28.6 ± 10.1 28.3 ± 9.3 0.89 1.029 (0.935-1.132) 0.56
Polyunsaturated fats* (g) 7.6 ± 3.9 7.3 ± 2.5 0.64 0.997 (0.708-1.403) 0.98
Fibers* (g) 22.5 ± 9.4 24.9 ± 8.8 0.18 1.008 (0.920-1.104) 0.87
Industrial fructose* (g) 5.5 ± 4.2 7.8 ± 6.0 0.01 1.205 (1.065-1.364) 0.003
Data are given as mean ± standard deviation or as number of case (%).
⁄Mean value of three-day dietary intake.
yr, years.
Letters to the Editorvariables must be reduced or the model must be simpliﬁed. In
order to include in the model the maximum number of variables
with a potential prognostic signiﬁcance, we choose a bivariate
conﬁrmation, so called ‘‘univariate’’, at the p threshold of 60.10
[2,3]. Accordingly, in our model the variable ‘‘energy intake’’
was not included because it was not signiﬁcantly associated with
the severity of ﬁbrosis. In any case, because candidate variables
may also be chosen from previous research or from clinical
experience, and considering the well-known relation between
industrial fructose and total energy intake, we repeated our
analyses adding ‘‘energy intake’’ in the model. This issue,
probably missed by Dr Chiavaroli and colleagues, was reported
at page 173 of the article [1] as follows ‘‘The association between
industrial fructose intake and severe liver ﬁbrosis did not change
when the presence of hypercaloric diet was forced into the model
as independent variable (OR 1.158, 95% CI 1.045–1.283,
p = 0.005).’’
Second, the authors also question that the analyses were not
corrected for other parameters not signiﬁcant at univariate anal-
ysis, but also known to be associated with metabolic alterations,
NAFLD, and unhealthy lifestyle, like several dietary nutrients,
smoking and exercise. Unfortunately in our population we did
not collect data on smoking and exercise, while data on nutrients
were available. After correction for an extensive panel of dietary
variables, industrial fructose intake remained signiﬁcant
associated with severe liver ﬁbrosis (Table 1).
In conclusion, our study supports the association between
industrial fructose intake and the severity of liver ﬁbrosis in
CHC patients. Along this line, while some studies attribute a
key pathogenic role for ﬁbrosis to energy intake [4–7], others
reported an association between fructose intake and the severity
of possibly associated metabolic disorders, including NAFLD
[8–12]. We are conﬁdent that the available evidence, including
our own data, will stimulate future research in this area to pro-
vide external validation based on prospective studies.174 Journal of Hepatology 20Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
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The ART strategy: Sequential assessment of the ART score predicts
outcome of patients with hepatocellular carcinoma
re-treated with TACE
To the Editor:
Hucke and colleagues are to be congratulated on their work pre-
dicting likely response to multiple cycles of transarterial chemo-
embolization (TACE) [1]. However, there are some issues that
need addressing.
Firstly, the authors assert that the ART score is derived from 3
variables. This is not true. The Child-Pugh score itself consists of 5
variables thus, it actually consists of 7 variables. In addition, the
greatest weighting for the ART score is not placed on evidence of
radiological response but on evidence of progressive cirrhosis and
worsening liver synthetic function. A rising aspartate amino-
transferase (AST) is well documented in advanced disease as a
marker of more severe cirrhosis [2,3]. It would have been useful
to have seen the individual biochemical constituents of the Child-
Pugh score and assessed their impact on predicting outcome.
An alternative score for predicting patient outcome after TACE
is available. The hepatoma arterial-embolization prognostic score
(HAP) was derived to assess likely response to TACE [4]. The score
was derived from a training set of 114 patients from which the
score was developed, and then validated in an independent sam-
ple of 167 patients. Patients were assigned 1 point for albumin
<36 g/dl, bilirubin >17 lmol/l, AFP >400 ng/ml, or size of domi-
nant lesion >7 cm, and has the advantage of not relying on assess-
ment of response to previous TACE. The score was calculated by
adding up their respective points. Patients were then divided into
four groups: HAP score 0 = A, HAP 1 = B, HAP 2 = C, HAP >2 = D.
The median survival for the respective groups was 27.6 months,
18.5 months, 9 months, and 3.6 months. Future studies in this
ﬁeld should compare the performance of both the ART strategy
and the HAP score to determine their applicability and how they
could best be used to help our patients.
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